Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 vs tofacitinib in rheumatoid arthritis (phase 2)
CTR20212789Phase 2Completed
- Sponsor
- Highlight Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of girocitinib in rheumatoid arthritis (RA), sponsored by Highlight Therapeutics. Started Nov 2021; status: completed.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20212789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212789.